Explore the vast range of titles available.

At Université Libre de Bruxelles (ULB), research was performed on a 1 kN lab-scale Hybrid Rocket Motor (the ULB-HRM). It has a single-port solid paraffin fuel grain and uses liquid N2O as an oxidizer. The first Computational Fluid Dynamics (CFD) model of the motor was developed in 2020 and improved in 2021, using ANSYS Fluent software. It is a 2D axisymmetric, two-phase steady-state Reynolds-Averaged Navier–Stokes (RANS) model, which uses the average fuel and oxidizer mass flow rates as inputs. It includes oxidizer spray droplets and entrained fuel droplets, therefore adding many additional parameters compared to a single-phase model. It must be investigated how they affect the predicted operating conditions. In this article, a sensitivity analysis is performed to determine the model’s robustness. It is demonstrated that the CFD model performs well within the boundaries of its purpose, with average deviations between predicted and experimental values of about 1% for the chamber pressure and 5% for the thrust. From the sensitivity analysis, multiple observations and conclusions are made. An important observation is that oxidizer related parameters have the highest potential impact, introducing deviations of the predicted operating chamber pressure of up to 18%, while this is only about 6% for fuel-related parameters. In general, the baseline CFD model of the ULB-HRM seems quite insensitive and it does not suffer from an excessive or abnormal sensitivity to any of the major parameters. Furthermore, the predicted operating conditions seem to respond in a logical and coherent way to changing input parameters. The model therefore seems sufficiently reliable to be used for future qualitative and quantitative predictions of the performance of the ULB-HRM.

Objective. To describe environmental contamination with hazardous drugs in a hospital pharmacy setting before and after reorganizing a hematology— oncology satellite pharmacy. Methods. This is a descriptive study of surface contamination with cyclophosphamide, ifosfamide, and methotrexate in two hematology—oncology satellite pharmacies. In order to measure surface contamination with hazardous drugs, samples from four distinct measurement sites within the pharmacy were taken in each of the two phases (pre-and postphases) using a sampling procedure and an analytical method modified from Larson et al. Results. A total of 133 samples from four measurement sites were taken and analyzed over the course of the study (specifically 60 prephase samples and 73 postphase samples). The study showed a significant increase in the number of positive samples (from 66.7% to 90.4%, p<0.001) from the pre- to the postphase. The increase, however, is only significant in terms of the location where completed preparations were placed after they had come out from under the hood (from 0/15 to 21/28, p<0.001) and the work surface (from 8/15 to 15/15, p = 0.006) and only in terms of ifosfamide. Furthermore, for the other sites studied, the number of positive samples remained unchanged between the pre- and postphase. A statistically significant difference between the pre- and postphase was observed in terms of ifosfamide for three of the four measurement sites studied and methotrexate for one of the four sites. Average concentrations were higher in the post phase in three of the four cases. Conclusion. This study describes environmental contamination with hazardous drugs in a hospital pharmacy setting before and after reorganizing a hematology—oncology satellite pharmacy. The study showed that a refitting of the hemato-oncology pharmacy is not a sufficient strategy to reduce the environmental contamination by ifosfamide because a significant increase in the number of positive samples from the pre- to the postphase have been observed. Many factors can contribute to influence the contamination of hazardous drugs such as the workflow and the training of the personal. Continuous environmental surveillance of hazardous drugs is required to document traces and help reduce risks. J Oncol Pharm Practice (2009) 15: 53—61.

Alan Astbury worked in the area of accelerator based subatomic physics. Increasing beam energies, intensities and types of available accelerated beams opened scientific windows to new phenomena throughout his career. Exploiting these new beams required new techniques and the use of the latest technology. Alan was always at the forefront of putting these components together into the experiments needed to confirm or reject the latest theoretical advances or clarify conflicting experimental observations. Following his PhD using the synchrocyclotron at the University of Liverpool and a postdoctoral position at Berkeley, he became a staff member at the Rutherford Appleton Laboratory, where he played a central role in the successive experiments with the Nimrod proton synchrotron, the 26 GeV proton synchrotron at CERN and, perhaps most significantly, with the UA1 experiment at CERN that discovered the W and Z particles. Alan moved to Canada in 1983 and made enormous contributions to Canadian science. He was instrumental in building relationships between Canadian scientists and CERN, DESY and SLAC. As director of the Canadian Institute of Particle Physics and then director of the TRIUMF laboratory, he guided subatomic physics policy and planning for two decades. On the international scene, he was president of the International Union of Pure and Applied Physics.

The Smithsonian Astrophysical Observatory (SAO) and the Centre National d’Études Spatiales (CNES) worked closely together in the early years of the space program to deploy satellite laser ranging (SLR) systems at overseas sites to enhance global coverage to support specific missions. The data were routinely made available for use by the science community for programs in geodesy, gravity field, atmospheric physics, and ultimately for oceanography and geodynamics. SAO and CNES organized campaigns for international participation and loaned each other equipment to enhance the network. SAO and CNES provided technical expertise and advice to a number of other groups as they planned and deployed SLR systems. In this paper, we will discuss the history and the role of the two institutions in the building of the international SLR network.

A bstract Preliminary ATLAS and CMS results from the first 13 TeV LHC run have encountered an intriguing excess of events in the diphoton channel around the invariant mass of 750 GeV. We investigate a possibility that the current excess is due to a heavy resonance decaying to light metastable states, which in turn give displaced decays to very highly collimated e + e − pairs. Such decays may pass the photon selection criteria, and successfully mimic the diphoton events, especially at low counts. We investigate two classes of such models, characterized by the following underlying production and decay chains: gg → S → A ′ A ′ → ( e + e − )( e + e − ) and q q ¯ → Z ′ → s a → e + e − e + e − , where at the first step a heavy scalar, S , or vector, Z ′ , resonances are produced that decay to light metastable vectors, A ′ , or (pseudo-)scalars, s and a . Setting the parameters of the models to explain the existing excess, and taking the ATLAS detector geometry into account, we marginalize over the properties of heavy resonances in order to derive the expected lifetimes and couplings of metastable light resonances. We observe that in the case of A ′ , the suggested range of masses and mixing angles ϵ is within reach of several new-generation intensity frontier experiments.

Purpose No occupational exposure limit exists for antineoplastic drugs. The main objective of this study was to describe environmental contamination with cyclophosphamide, ifosfamide and methotrexate in pharmacy and patient care areas of Canadian hospitals in 2012. The secondary objective was to compare the 2012 environmental monitoring results with the 2008–2010 results. Methods Six standardized sites in the pharmacy and six sites on patient care areas were sampled in each participating center. Samples were analyzed for the presence of cyclophosphamide, ifosfamide and methotrexate by UPLC-MS-MS. The limit of detection (LOD) was 1.8 pg/cm 2 for cyclophosphamide, 2.2 pg/cm 2 for ifosfamide and 8.0 pg/cm 2 for methotrexate. The comparison of surface contamination between the 2008–2010 and 2012 studies was made with the 75th percentile of cyclophosphamide concentration. Results A total of 33 hospitals participated in the study and 363 samples were collected. Overall, 40 % (147/363) of the samples were positive for cyclophosphamide, 18 % (68/363) were positive for ifosfamide and 5 % (17/363) were positive for methotrexate. In 2012, the 75th percentile value of cyclophosphamide surface concentration was of 9.4 pg/cm 2 , which is four times lower than the 2008–2010 75th percentile of 40 pg/cm 2 . In both studies, the 75th percentile for ifosfamide and methotrexate concentration was lower than the LOD. Conclusions Surface contamination by cyclophosphamide, ifosfamide and methotrexate in Canadian hospitals is improving both in terms of the proportions of positive samples and in terms of the surface concentration of antineoplastic drugs. A local 75th percentile value should be use to assess local contamination and interpret local results.